Results 31 to 40 of about 50,593 (147)

MYH3‐associated distal arthrogryposis zebrafish model is normalized with para‐aminoblebbistatin

EMBO Molecular Medicine, 2020
Distal arthrogryposis (DA) is group of syndromes characterized by congenital joint contractures. Treatment development is hindered by the lack of vertebrate models.
Julia Whittle, Lilian Antunes, Mya Harris, Zachary Upshaw, Diane S Sepich, Aaron N Johnson, Mayssa Mokalled, Lilianna Solnica‐Krezel, Matthew B Dobbs, Christina A Gurnett   +9 more
doaj   +1 more source

Rho-Associated Kinases and Non-muscle Myosin IIs Inhibit the Differentiation of Human iPSCs to Pancreatic Endoderm

Stem Cell Reports, 2017
Summary: There has been increasing success with the generation of pancreatic cells from human induced pluripotent stem cells (hiPSCs); however, the molecular mechanisms of the differentiation remain elusive.
Taro Toyoda, Azuma Kimura, Hiromi Tanaka, Tomonaga Ameku, Atsushi Mima, Yurie Hirose, Masahiro Nakamura, Akira Watanabe, Kenji Osafune   +8 more
doaj   +1 more source

Spheroid Fabrication Using Concave Microwells Enhances the Differentiation Efficacy and Function of Insulin-Producing Cells via Cytoskeletal Changes

Cells, 2020
Pancreatic islet transplantation is the fundamental treatment for insulin-dependent diabetes; however, donor shortage is a major hurdle in its use as a standard treatment. Accordingly, differentiated insulin-producing cells (DIPCs) are being developed as
Yu Na Lee, Hye Jin Yi, Hanse Goh, Ji Yoon Park, Sarah Ferber, In Kyong Shim, Song Cheol Kim   +6 more
doaj   +1 more source

A New Era in the Management of Hypertrophic Cardiomyopathy

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Ana Perez-Asensio, Helena Llamas-Gomez, Ana Lara-Palomo, Alberto Villar-Ruiz, Cesar Jimenez-Mendez, Julian Palomino-Doza   +5 more
doaj   +1 more source

Novel Antimalarial Inhibitors That Specifically Target the Invasion Motor Protein Myosin A in Malaria Parasites

Proceedings, 2019
Malaria remains a devastating disease with nearly half a million deaths per year. The WHO reports a stagnating number of new infections every year without a significant decline, as a result of insufficient access to antimalarials in endemic regions as ...
Janna Ehlert, Arne Alder, Viola Introini, Julia Weder, Pietro Cicuta, Tim W. Gilberger, Matthias Preller   +6 more
doaj   +1 more source

A Myosin V Inhibitor Based on Privileged Chemical Scaffolds [PDF]

Angewandte Chemie International Edition, 2010
Small molecules that perturb the function of their targets on fast-time scales can be powerful probes of dynamic cellular processes, such as intracellular transport.[1] In the past decade, inhibitors for motor proteins, ATPases that drive movements of cellular cargoes, have been reported.[2] These chemical inhibitors (with μM potency) have served as ...
Kabirul, Islam, Harvey F, Chin, Adrian O, Olivares, Lauren P, Saunders, Enrique M, De La Cruz, Tarun M, Kapoor   +5 more
openaire   +2 more sources

Clinical Trials in Hypertrophic Cardiomyopathy Therapy: A Comprehensive Analysis of Trials Registered in Global Clinical Databases

Drug Design, Development and Therapy, 2023
Huan Zhang,1,2,* Cheng Yu,1,* Yuanling Cheng,1 Zhi Chen,2 Min Chen,2 Wangan He,1 Zhigang Jin,1 Shaoqian Cai,1 Lijuan Yu2 1Department of Cardiology, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan ...
Zhang H, Yu C, Cheng Y, Chen Z, Chen M, He W, Jin Z, Cai S, Yu L   +8 more
doaj  

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy

European Heart Journal, 2023
Abstract Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target the hyper-contractile phenotype,
Braunwald, Eugene, Saberi, Sara, Abraham, Theodore P, Elliott, Perry M, Olivotto, Iacopo   +4 more
openaire   +6 more sources

Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report

Monaldi Archives for Chest Disease
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes, João Gomes Carvalho, Patrícia Rodrigues, Manuela França   +3 more
doaj   +1 more source

A novel 2.5D culture platform to investigate the role of stiffness gradients on adhesion-independent cell migration. [PDF]

PLoS ONE, 2014
Current studies investigating the role of biophysical cues on cell migration focus on the use of culture platforms with static material parameters. However, migrating cells in vivo often encounter spatial variations in extracellular matrix stiffness.
Mark-Phillip Pebworth, Sabrina A Cismas, Prashanth Asuri   +2 more
doaj   +1 more source